论文部分内容阅读
目的观察盖诺联合卡培他滨方案治疗晚期乳腺癌的临床疗效和不良反应。方法34例晚期乳腺癌患者应用盖诺25mg/m2,d1、8,静注;卡培他滨2000mg/m2,分两次口服,d114,21d为1周期。化疗过程中注意观察不良反应,连用2周期后按照WHO标准进行疗效及毒副反应评价。结果34例均可以进行疗效评价,CR4例,PR16例,SD12例,PD2例,总有效率58.8%。不良反应主要为骨髓抑制、消化道反应和手足综合征等。结论盖诺联合卡培他滨方案治疗晚期乳腺癌疗效好,毒性低,使用方便、经济,患者耐受性好。
Objective To observe the clinical efficacy and adverse reactions of the combination of capecitabine and capecitabine in the treatment of advanced breast cancer. Methods 34 patients with advanced breast cancer were treated with Gentamycin 25mg / m2, d1,8, intravenously; capecitabine 2000mg / m2 orally twice daily for d114,21d. Adverse reactions observed during chemotherapy, once every 2 cycles in accordance with the WHO standards for efficacy and toxicity evaluation. Results All the 34 cases could be evaluated with CR4, PR16, SD12 and PD2, the total effective rate was 58.8%. Adverse reactions mainly bone marrow suppression, gastrointestinal reactions and hand-foot syndrome. Conclusions The combination of capecitabine and capecitabine is effective in treating advanced breast cancer. Its toxicity is low, it is easy to use, economical and well tolerated.